FIELD: IL-2 conjugates.
SUBSTANCE: invention is related to IL-2 conjugates or pharmaceutically acceptable salts thereof, pharmaceutical compositions containing such an IL-2 conjugate or a pharmaceutically acceptable salt thereof, and uses thereof.
EFFECT: IL-2 conjugates are proposed.
16 cl, 2 tbl, 14 ex
| Title | Year | Author | Number |
|---|---|---|---|
| OPTIMIZED OPTIONS OF ANTI-VEGF ANTIBODIES | 2016 |
|
RU2763916C2 |
| DRY PHARMACEUTICAL FORMULATIONS OF CNP CONJUGATE | 2020 |
|
RU2830251C2 |
| LIQUID PHARMACEUTICAL FORMULATIONS OF PTH CONJUGATES | 2020 |
|
RU2817015C2 |
| INTERLEUKIN 10 CONJUGATES AND APPLICATIONS THEREOF | 2020 |
|
RU2829811C1 |
| IL-2 CONJUGATES AND METHODS OF USE THEREOF | 2020 |
|
RU2829327C2 |
| OPTIMIZED ANTIBODY COMPOSITIONS FOR TREATMENT OF EYE DISEASES | 2018 |
|
RU2782355C2 |
| PRODRUG COMPOSITIONS BASED ON CROSS-LINKED HYALURONIC ACID HYDROGEL AND METHODS OF THEIR PRODUCTION | 2018 |
|
RU2812787C2 |
| CNP PRODRUGS | 2016 |
|
RU2824988C1 |
| TYPES OF IMMUNO-ONCOLOGICAL COMBINATION THERAPY USING IL-2 CONJUGATES | 2020 |
|
RU2840258C2 |
| CONTROLLED RELEASE COMBINATION THERAPY WITH CNP AGONISTS | 2017 |
|
RU2768747C2 |
